Omission of Text in Financial Disclosures: In the Original Contribution entitled “Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial” published in the November 15, 2006, issue of JAMA (2006;296:2319-2328), text in 2 sentences of the financial disclosure was inadvertently omitted. The sentence that read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, a consultant for Allergan and Esprit, a speaker for Astellas and Esprit, and a study investigator for Allergan and Q-Med” should have read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, and is a study investigator for Lilly ICOS. Dr Rovner is a paid consultant, speaker, meeting participant, and study investigator for Pfizer; a consultant for Allergan and Esprit; a speaker for Astellas and Esprit; and a study investigator for Allergan and Q-Med.”